MiR-200c and HuR in ovarian cancer (Q21261258)

18 August 2022

7

Shohreh Shahabi

Shohreh

Shahabi

1 reference

18 August 2022

4

Giuseppina Raspaglio

Giuseppina

Raspaglio

1 reference

18 August 2022

3

Marisa Mariani

Marisa

Mariani

1 reference

18 August 2022

1

Silvia Prislei

Silvia

Prislei

1 reference

18 August 2022

Cristiano Ferlini

9

Cristiano

Ferlini

1 reference

18 August 2022

Enrica Martinelli

2

Enrica

Martinelli

1 reference

18 August 2022

Steven Sieber

series ordinal

5

author given names

Steven

author last names

Sieber

1 reference

18 August 2022

Gabriella Ferrandina

author given names

Gabriella

author last names

Ferrandina

series ordinal

6

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-13-72

18 August 2022

language of work or name

English

0 references

publication date

2013

0 references

published in

BMC Cancer

0 references

volume

13

0 references

issue

1

0 references

page(s)

72

0 references

exact match

0 references

cites work

The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

The widespread regulation of microRNA biogenesis, function and decay

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

Posttranscriptional regulation of cancer traits by HuR

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

HuR regulates beta-tubulin isotype expression in ovarian cancer

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

Causes and consequences of microRNA dysregulation in cancer

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

Molecular mechanisms of patupilone resistance

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

MicroRNA signatures in human ovarian cancer

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

Post-transcriptional stimulation of gene expression by microRNAs

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

MicroRNA regulation by RNA-binding proteins and its implications for cancer

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

MicroRNAs in ovarian cancer biology and therapy resistance.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

Role of hypoxia in the hallmarks of human cancer

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3576328

MicroRNA expression profiles in serous ovarian carcinoma.

27 September 2017

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-13-72

Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-13-72

Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-13-72

Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23394580

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The miR-200 family controls -tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23394580

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-13-72

1 reference

3008242

0 references

3008242

1 reference

1 reference

1 reference